Oragenics (NYSE American: OGEN) Announces Audit Opinion Highlighting Going Concern
Key Developments Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotech focused on brain-targeted therapeutics, has received an unqualified audit opinion from its independent accounting firm. This opinion, included in the company’s Annual Report on Form 10-K for 2025 filed on March 16, 2026, features an explanatory paragraph regarding the company’s status as a going concern. The disclosure is in line with NYSE American LLC regulations, specifically Company Guide Section 610(b),…
